Finzati - Logo
HROW logo

Harrow Health, Inc.

HROW • Drug Manufacturers - Specialty & Generic
$38.54
▲ +0.28 (+0.73%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$1.44B
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Positive revenue growth · 28.6%Positive free cash flow · 1.17Healthy liquidity · 2.2High debt level · 4.8Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 12, 2026, 12:12 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$38.54
Change0.73%
Shares Out37.35M
Market Cap$1.44B
Enterprise Value$1.66B
52W Range28.54 - 54.85
Beta0.26
P/E-38.67
P/S5.22
P/B96.97
P/FCF260.73
EV/Sales6.01

Investment DNA

How strong this company looks for long-term investors

55
out of 100
Business Quality
Margins, moat, returns
37/100
Financial Strength
Debt, cash, stability
58/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
29/100
Why this score▼
Positive revenue growth · 28.6%Positive free cash flow · 1.17Healthy liquidity · 2.2High debt level · 4.8Weak profitability

Analyst view

Analyst sentiment and price target

HROW
Analyst sentiment
Based on 10 analyst votes · 2026-09-04
100/100
Bullish
Bullish
10
Hold
0
Bearish
0
Price Target
2026-08-12
Low
$63.00
Mean
$73.67
Median
$70.00
High
$88.00

Company Overview

IPO: 9/28/2007
Industry: Drug Manufacturers - Specialty & Generic
P/B i: 96.97
Debt / Equity i: 4.80
Operating Margin: 14.18%
Net Margin: -1.89%
ROE i: -
ROIC: -

Financial Health

Score12 / 20
Debt / Equity: 4.80
Current Ratio: 2.20
Quick Ratio: 2.06
Status: Good

Warnings

  • High debt level

Insider Transactions

Recent executive and insider activity

⚠ 1 high-volume insider sell detected
Graves Adrienne L
Transaction: 06/18/2026
BUY
Change
+5,248
Price
Not reported
Filing
06/22/2026
Type
BUY
SILVERNAIL LAUREN P
Transaction: 06/18/2026
BUY
Change
+5,248
Price
Not reported
Filing
06/22/2026
Type
BUY
Sternberg Perry J.
Transaction: 06/18/2026
BUY
Change
+5,248
Price
Not reported
Filing
06/22/2026
Type
BUY